Watch out Gilead, GSK’s Vi­iV is steam­ing ahead with promis­ing late-stage da­ta on a two-drug HIV ther­a­py

One of the few bright spots in Glax­o­SmithK­line’s late-stage pipeline has come through in a pair of Phase III stud­ies. The phar­ma gi­ant says in­ves­ti­ga­tors scored pos­i­tive da­ta from both Phase III stud­ies de­signed to de­ter­mine if pa­tients could safe­ly switch from mul­tidrug cock­tails to a com­bi­na­tion of do­lute­gravir from Vi­iV Health­care and J&J’s rilpivirine.

The out­come sets up reg­u­la­to­ry fil­ings for Vi­iV in a loom­ing 2017, says the phar­ma gi­ant, which is al­lied with Pfiz­er and Sh­iono­gi on the joint ven­ture. And it al­so pos­es a new threat for Gilead, which has long re­lied on its block­buster HIV rev­enue from its mul­ti-drug cock­tail reg­i­mens to fi­nance the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER